Markets:

Overview

News

Currencies

International

Treasuries

Indivior PLC - Ordinary Shares (NQ:INDV)

34.00 +0.40 (+1.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Indivior PLC - Ordinary Shares

< Previous 1 2 3 Next >

Here's Why Indivior Stock Soared 15% Today ↗

October 30, 2025

This company is accelerating sales growth in its key prescription medication.

Via The Motley Fool

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

INDIVIOR PLC (NASDAQ:INDV) Shows Top Technical and Setup Ratings for Potential Breakout ↗

October 20, 2025

INDIVIOR (INDV) shows strong technicals with a perfect 10 rating and a 9 setup score, signaling a potential breakout above $25.20 resistance.

Via Chartmill

This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

August 06, 2025

Via Benzinga

Indivior (INDV) Q2 EPS Jumps 104% ↗

August 01, 2025

Via The Motley Fool

Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For April 24, 2025 ↗

April 24, 2025

Via Benzinga

Indivior (INDV) Q1 2025 Earnings Call ↗

April 24, 2025

Via The Motley Fool

A Look at Indivior's Upcoming Earnings Report ↗

April 23, 2025

Via Benzinga

Indivior PLC: Is This Deeply Undervalued Stock A Hidden Gem? ↗

April 13, 2025

With a strong position in a niche yet vital therapeutic area, Indivior PLC benefits from durable brand equity, a specialized distribution network, and a long runway for product innovation.

Via Talk Markets

Topics Stocks / Equities

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat ↗

February 20, 2025

Indivior's 2025 outlook missed estimates, citing Suboxone sales erosion. The company plans $100 million in cost cuts, with $50M reinvested in Sublocade.

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

February 20, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Tesla, A. O. Smith And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

October 11, 2024

Via Benzinga

S&P Moves Lower; Domino's Pizza Posts Mixed Q3 Results ↗

October 10, 2024

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 10, 2024

Via Benzinga

Crude Oil Surges 3%; Delta Air Lines Posts Downbeat Earnings ↗

October 10, 2024

Via Benzinga

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details ↗

October 10, 2024

Indivior cuts FY24 net revenue outlook due to competition and funding delays, causing a drop in share price.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 10, 2024

Via Benzinga

Top 3 Health Care Stocks That May Explode This Month ↗

September 23, 2024

Via Benzinga

Smith & Wesson Brands Reports Downbeat Results, Joins Planet Labs PBC, Broadcom And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

September 06, 2024

Via Benzinga

French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option ↗

September 04, 2024

Via Benzinga

Topics Cannabis

Health And Human Services Dept Orders OPVEE Nasal Spray For Emergency Fentanyl Overdose Response ↗

August 27, 2024

Via Benzinga

Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder ↗

August 27, 2024

Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the...

Via Benzinga

DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 26, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

July 25, 2024

Pre-market stock movers are a hot topic on Thursday morning and we have all of the latest news traders need to know about them!

Via InvestorPlace

INDV Stock Earnings: Indivior Beats EPS, Beats Revenue for Q2 2024 ↗

July 25, 2024

INDV stock results show that Indivior beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 25, 2024

Via Benzinga

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

July 25, 2024

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.